1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 12,260 | 12,340 | 20:22 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.09. | Devyser Diagnostics AB: Bulletin from an Extraordinary General Meeting in Devyser Diagnostics AB (publ) held on 22 September 2025 | 84 | GlobeNewswire (Europe) | An Extraordinary General Meeting of Devyser Diagnostics AB (publ) ("Devyser" or the "Company") was held on Monday, 22 September 2025 at Bränningevägen 12, 120 54 Årsta. The main resolution passed at... ► Artikel lesen | |
| 15.08. | Devyser im zweiten Quartal 2025: Umsatz steigt um 27 % bei Rückkehr in die Gewinnzone | 1 | Investing.com Deutsch | ||
| 15.08. | Devyser Q2 2025 presentation: Revenue jumps 27% as profitability returns | 3 | Investing.com | ||
| 22.07. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2025 | 141 | GlobeNewswire (Europe) | "A positive operating result was recorded in the second quarter. The effects of the cost-cutting program initiated at the beginning of the year can already be seen in both current costs and in the cost... ► Artikel lesen | |
| 30.06. | Devyser Diagnostics AB: Devyser launches Genomic Blood Typing assay: All blood groups, one simple test | 155 | GlobeNewswire (Europe) | Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation sequencing (NGS)-based solution that redefines molecular blood group research. Developed exclusively, this... ► Artikel lesen | |
| 29.04. | Devyser Q1 2025 slides reveal mixed results with 8% growth, EBIT challenges | 1 | Investing.com | ||
| 29.04. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2025 | 382 | GlobeNewswire (Europe) | "A quarter has passed since I took over as acting CEO and it has been an eventful first few months. Despite the turbulent environment, marked by geopolitical uncertainty, we are able to report our second... ► Artikel lesen | |
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 14.04. | Devyser Diagnostics AB: Jan Wahlström new CEO for Devyser | 253 | GlobeNewswire (Europe) | Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science areas internationally.... ► Artikel lesen | |
| 19.02. | Devyser Diagnostics AB: Devyser secures a major SEK 16.8M tender in Italy with 30% growth | 249 | GlobeNewswire (Europe) | Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical genetic markers.... ► Artikel lesen | |
| 13.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2024 | 385 | GlobeNewswire (Europe) | "Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust development... ► Artikel lesen | |
| 28.01. | Devyser Diagnostics AB: Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.4 million SEK | 204 | GlobeNewswire (Europe) | Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK
"This... ► Artikel lesen | |
| 16.01. | Devyser Diagnostics AB: Devyser publishes preliminary result for Q4 2024 | 727 | GlobeNewswire (Europe) | In light of this morning's communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for 2024 before... ► Artikel lesen | |
| 30.10.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period July to September 2024 | 153 | GlobeNewswire (Europe) | "It is very gratifying to see the impact that we are having in the field of diagnostics. I have just returned from the ASHI event, a major transplantation conference in the US, and it is clear that... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 82,70 | -0,92 % | MEDTRONIC (ISIN: IE00BTN1Y115; 98,30 $) beendet dreijährige Seitwärtsbewegung | Solche langen Bodenbildungsphasen mit abschließendem Kaufsignal haben in der Regel eine hohe Aussagekraft. CFO Thierry Pieton bekräftigt für das kommende Geschäftsjahr ein Wachstum beim Gewinn je Aktie... ► Artikel lesen | |
| HCA HEALTHCARE | 360,00 | -0,63 % | What to Expect From HCA Healthcare's Q3 2025 Earnings Report | ||
| LANTHEUS | 46,120 | +1,74 % | What 6 Analyst Ratings Have To Say About Lantheus Holdings | ||
| ENVISTA | 17,700 | +1,14 % | Envista Holdings Corporation: Envista Reports Second Quarter 2025 Results | BREA, Calif., July 31, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended June 27, 2025.
"Envista achieved... ► Artikel lesen | |
| CAREDX | 12,630 | +0,32 % | CareDx, Inc.: CareDx präsentiert neue IVD-Produkte und IVDR-Zertifizierung für AlloSeq Tx und QTYPE bei der Jahrestagung 2025 der American Society of Histocompatibility & Immunogenetics | Festigung der weltweiten Führungsrolle bei der HLA-Typisierung von Spenderorganen und Transplantatempfängern
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company ein führendes Unternehmen auf dem... ► Artikel lesen | |
| GT BIOPHARMA | 0,680 | -12,82 % | GT Biopharma, Inc.: GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies | The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns... ► Artikel lesen | |
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fourth Quarter and Fiscal Year 2025 Results | Reports 36% YoY Platform Revenue Increase, ARR of $20.9 Million and Record Fiscal Year Net Income and Adjusted EBITDA
HENDERSON, Nev., Sept. 18, 2025 /PRNewswire/... ► Artikel lesen | |
| CARMAT | 0,099 | -100,00 % | CARMAT Provides an Update on the Ongoing Receivership Procedure | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
| CHEMOMETEC | 91,45 | -0,60 % | Dividendenbekanntmachungen (10.10.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,63 USD 1,4094 EUR ADVANCE AUTO PARTS INC US00751Y1064 0,25 USD 0,2161 EUR ALTAI RESOURCES INC CA02136K1084 0... ► Artikel lesen | |
| ARRAIL GROUP | 0,218 | 0,00 % | ARRAIL GROUP (06639): POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON SEPTEMBER 26, 2025 | ||
| POLAREAN IMAGING | 0,007 | 0,00 % | Polarean Imaging expands partnership with Ascend to cover 19 US states | ||
| PROMIMIC | 1,550 | +8,01 % | Curiteva & Promimic - Bonded by Innovation | HUNTSVILLE, ALABAMA / ACCESS Newswire / May 6, 2025 / Curiteva, a leader in 3D-printed Trabecular PEEK implant technology, is pleased to announce an expanded partnership with Promimic, pioneers in nanotechnology... ► Artikel lesen | |
| GERRESHEIMER | 28,760 | -5,83 % | Gerresheimer, Nordex, Renk Group, Siltronic, Redcare Pharmacy - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 47,210 | -2,64 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Jefferies hat Siemens Healthineers auf "Buy" mit einem Kursziel von 60 Euro belassen. Der Medizintechnikkonzern gehöre ebenso wie Amadeus IT, Assa Abloy, Gjensidige, Heineken... ► Artikel lesen | |
| FRESENIUS | 47,700 | -0,93 % | PTA-Adhoc: PORR AG: PORR vereinbart Erwerb des österreichischen Projektentwicklungsgeschäfts und Thermenbeteiligungen von Fresenius/VAMED | DJ PTA-Adhoc: PORR AG: PORR vereinbart Erwerb des österreichischen Projektentwicklungsgeschäfts und Thermenbeteiligungen von Fresenius/VAMED
Veröffentlichung von Insiderinformationen gemäß Artikel... ► Artikel lesen |
DEVYSER DIAGNOSTICS AB gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von +0,140 (+1,14 %) liegt der Kurs bei 12,460 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.